Investor Presentaiton

5 IDEAYA Leadership Team and Scientific Advisory Board Experienced Team & Scientific Thought Leaders in Precision Medicine Oncology IDEAYA Executives & R&D Leadership Yujiro Hata, M.B.A. Chief Executive Officer, Director FLEXUS ONYX ENANTA AMGEN BIOSCIENCES Bristol-Myers Squibb Pharmaceuticals Matthew Maurer, M.D. Head of Clinical Oncology & Medical Affairs Bristol-Myers Squibb COLUMBIA Darrin Beaupre, M.D., Ph.D. Chief Medical Officer Pfizer pharmacyclics AMGEN Mick O'Quigley, M.B.A. Head of Development Operations Genentech AMGEN Michael White, Ph.D. Chief Scientific Officer Pfizer UT Southwestern Medical Center. Paul Barsanti, Ph.D. Chief Technology Officer AM VENTURES 5 nurix NOVARTIS CHIRON Paul Stone, J.D. Chief Financial Officer 5AM VENTURES ILYPSA AMGEN Jason Throne, J.D. Chief Legal Officer 0 neotract THORATEC CORPORATION IDEAYA Scientific Advisory Board Frank McCormick, Ph.D. SAB Chair UCSF, Professor and former Director, Helen Diller Cancer Center Former President AACR; Founder and CSO, Onyx Karlene Cimprich, Ph.D. Professor, Chemical and Systems Biology and (by courtesy) Biochemistry, Member, Stanford Cancer Institute, Stanford University Trey Ideker, Ph.D. UCSD, Professor, Co-Director Cancer Genomes & Networks Program, Research in Dual-CRISPR and SL interaction maps Kornelia Polyak, M.D., Ph.D. Professor of Medicine at Dana-Farber Cancer Institute, Harvard Medical School, and a co-leader of the Dana-Farber Harvard Cancer Center Cancer Cell Biology Program William Sellers, M.D. Broad Institute, Dana Farber, and Harvard, Professor Novartis, Former Head Oncology Research, SL Project Drive initiative Elizabeth Swisher, M.D. University of Washington, Professor; Co-Leader, Breast and Ovarian Cancer Research Program, Seattle Cancer Care Alliance Principal Investigator on multiple PARP inhibitor trials IDEAVA BIOSCIENCES

View entire presentation